C H Miller

Summary

Affiliation: Centers for Disease Control and Prevention
Country: USA

Publications

  1. doi request reprint Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study
    C H Miller
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Thromb Haemost 11:1300-9. 2013
  2. doi request reprint Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance
    C H Miller
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Thromb Haemost 10:1055-61. 2012
  3. doi request reprint F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity
    C H Miller
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Haemophilia 18:375-82. 2012
  4. ncbi request reprint Laboratory tests for the diagnosis of thrombotic disorders
    Connie H Miller
    Division of Hereditary Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia 30345, USA
    Clin Obstet Gynecol 49:844-9. 2006
  5. doi request reprint The spectrum of haemostatic characteristics of women with unexplained menorrhagia
    C H Miller
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Haemophilia 17:e223-9. 2011
  6. ncbi request reprint Elevated factor VII as a risk factor for recurrent fetal loss. Relationship to factor VII gene polymorphisms
    Connie H Miller
    Division of Hereditary Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop D 02, Atlanta, Georgia 30333, USA
    Thromb Haemost 93:1089-94. 2005
  7. ncbi request reprint Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women
    C H Miller
    Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Am J Hematol 67:125-9. 2001
  8. pmc In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service and Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
    J Thromb Haemost 8:2224-31. 2010
  9. ncbi request reprint Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor
    Connie H Miller
    Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Thromb Haemost 88:56-9. 2002
  10. doi request reprint A study of prospective surveillance for inhibitors among persons with haemophilia in the United States
    J M Soucie
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Haemophilia 20:230-7. 2014

Collaborators

Detail Information

Publications14

  1. doi request reprint Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study
    C H Miller
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Thromb Haemost 11:1300-9. 2013
    ..Detection and validation of inhibitors (antibodies) to hemophilia treatment products are important for clinical care, evaluation of product safety and assessment of population trends...
  2. doi request reprint Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance
    C H Miller
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Thromb Haemost 10:1055-61. 2012
    ..As part of a pilot U.S. inhibitor surveillance project initiated at the Centers for Disease Control and Prevention (CDC) in 2006, a centralized inhibitor measurement was instituted...
  3. doi request reprint F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity
    C H Miller
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Haemophilia 18:375-82. 2012
    ..White patients with history of inhibitor did not exhibit rare F8 haplotypes. F8 gene analysis did not reveal a cause for the higher inhibitor frequencies in Black and Hispanic patients...
  4. ncbi request reprint Laboratory tests for the diagnosis of thrombotic disorders
    Connie H Miller
    Division of Hereditary Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia 30345, USA
    Clin Obstet Gynecol 49:844-9. 2006
    ..These changes make some thrombotic disorders difficult to diagnose during pregnancy. Testing before pregnancy for women with a personal or family history of thrombosis will simplify the interpretation...
  5. doi request reprint The spectrum of haemostatic characteristics of women with unexplained menorrhagia
    C H Miller
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Haemophilia 17:e223-9. 2011
    ..S. sites. To what degree these abnormalities are clinically significant requires further study...
  6. ncbi request reprint Elevated factor VII as a risk factor for recurrent fetal loss. Relationship to factor VII gene polymorphisms
    Connie H Miller
    Division of Hereditary Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop D 02, Atlanta, Georgia 30333, USA
    Thromb Haemost 93:1089-94. 2005
    ..No other promoter polymorphisms were identified. This is the first report of a significant elevation of FVII in a population with recurrent fetal loss. These data suggest the need for further investigation of this potential risk factor...
  7. ncbi request reprint Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women
    C H Miller
    Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Am J Hematol 67:125-9. 2001
    ..The finding of increased vWF:Ag not accompanied by increased vWF:RCof has implications for understanding the structure-function relationships of vWF. Published 2001 Wiley-Liss, Inc...
  8. pmc In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service and Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA
    J Thromb Haemost 8:2224-31. 2010
    ..Although intensive FVIII treatment has long been considered a risk factor for inhibitor development in those with non-severe disease, its strength of association and the influence of other factors have remained undefined...
  9. ncbi request reprint Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor
    Connie H Miller
    Hematologic Diseases Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Thromb Haemost 88:56-9. 2002
    ..93. The CDC in-house method was compared to the BC Reagent method in 79 additional menorrhagia cases, with r = .94. The automated methods produced results equivalent or superior to those of traditional methods of measuring VWF:RCo...
  10. doi request reprint A study of prospective surveillance for inhibitors among persons with haemophilia in the United States
    J M Soucie
    Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Haemophilia 20:230-7. 2014
    ....
  11. ncbi request reprint Factor V Leiden and factor V R2 allele: high-throughput analysis and association with venous thromboembolism
    J M Benson
    Hematologic Diseases Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Thromb Haemost 86:1188-92. 2001
    ..S. Caucasians, 5.6% in African-Americans, 13.4% in Asian or Pacific Islanders and 11.3% in Hispanics. No association between venous thromboembolism and the R2 allele was noted, and furthermore no interaction with FV Leiden was observed...
  12. ncbi request reprint Measurement of von Willebrand factor activity: relative effects of ABO blood type and race
    C H Miller
    Hematologic Diseases Branch, NCID DASTLR, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop D 02, Atlanta, GA 30333, USA
    J Thromb Haemost 1:2191-7. 2003
    ..This heterogeneity within the normal population is partially responsible for the difficulty in defining diagnostic limits for von Willebrand disease...
  13. ncbi request reprint Age and the prevalence of bleeding disorders in women with menorrhagia
    Claire S Philipp
    Department of Medicine, UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
    Obstet Gynecol 105:61-6. 2005
    ..A study was conducted to evaluate the frequency and types of hemostatic defects occurring in adolescent and perimenopausal-age women diagnosed with menorrhagia...
  14. ncbi request reprint Changes in von Willebrand factor and factor VIII levels during the menstrual cycle
    Connie H Miller
    Thromb Haemost 87:1082-3. 2002